Financiado en parte por Amgen, Regeneron Pharmaceuticals
Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress
Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, Jones P, Ramprasath VR, O'Hara G, Kopecky S, Brophy JM, Tardif JC, AFFORD Investigators
Journal of the American College of Cardiology · 73 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Amgen
- Organización sin fines de lucro
- Heart and Stroke Foundation of Canada
- Empresa
- Regeneron Pharmaceuticals
- Organización sin fines de lucro
- Heart And Stroke Foundation Of Quebec
- Gobierno
- Canadian Institutes of Health Research
- Subvenciones
- Canadian Institutes of Health Research (MCT88068)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2014-09-29 · J Am Coll Cardiol · vol. 64 · número 14 · págs. 1441–1448
- Editorial
- Elsevier BV
- Citado
- 93 citas · más que el 98% de estudios similares · 8.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Atrial Fibrillation Management and Outcomes · Fatty Acid Research and Health · Blood properties and coagulation
- Palabras clave
- fish oil, omega-3 fatty acids, atrial fibrillation, atrial fibrillation recurrence, inflammation, oxidative stress, C-reactive protein, myeloperoxidase, paroxysmal atrial fibrillation, persistent atrial fibrillation, antiarrhythmic therapy
- MeSH
- animals, fishes, humans, atrial fibrillation, recurrence, inflammation, peroxidase, fatty acids, omega-3, fish oils, c-reactive protein, anti-arrhythmia agents, treatment outcome, proportional hazards models, double-blind method, oxidative stress, time factors, dietary supplements, aged, middle aged, female, male
12 autores
- Anil Nigam🇨🇦 · autor de correspondenciaMontreal Heart Institute; Université de Montréal
- Mario R. Talajic🇨🇦Montreal Heart Institute; Université de Montréal
- Denis Roy🇨🇦Montreal Heart Institute; Université de Montréal
- Stanley Nattel🇨🇦Montreal Heart Institute; Université de Montréal
- Jean Lambert🇨🇦Université de Montréal
- Anna Nozza🇨🇦Université de Montréal
- Peter J.H. Jones🇨🇦University of Manitoba
- Vanu Ramkumar Ramprasath🇨🇦University of Manitoba
- Gilles E O’Hara🇨🇦Institut universitaire de cardiologie et de pneumologie de Québec
- Stephen Louis Kopecky🇺🇸Mayo Clinic
- James M. Brophy🇨🇦McGill University Health Centre
- Jean‐Claude Tardif🇨🇦Montreal Heart Institute; Université de Montréal
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Recent trials of fish oil for the prevention of atrial fibrillation (AF) recurrence have provided mixed results. Notable uncertainties in the existing evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress in patients with paroxysmal or persistent AF not receiving conventional antiarrhythmic (AA) therapy.
Objectives
The aim of this study was to evaluate the influence of high-dose fish oil on AF recurrence, inflammation, and oxidative stress parameters.
Methods
We performed a double-blind, randomized, placebo-controlled, parallel-arm study in 337 patients with symptomatic paroxysmal or persistent AF within 6 months of enrollment. Patients were randomized to fish oil (4 g/day) or placebo and followed, on average, for 271 ± 129 days.
Results
The primary endpoint was time to first symptomatic or asymptomatic AF recurrence lasting >30 s. Secondary endpoints were high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO). The primary endpoint occurred in 64.1% of patients in the fish oil arm and 63.2% of patients in the placebo arm (hazard ratio: 1.10; 95% confidence interval: 0.84 to 1.45; p = 0.48). hs-CRP and MPO were within normal limits at baseline and decreased to a similar degree at 6 months (Δhs-CRP, 11% vs. -11%; ΔMPO, -5% vs. -9% for fish oil vs. placebo, respectively; p value for interaction = NS).
Conclusions
High-dose fish oil does not reduce AF recurrence in patients with a history of AF not receiving conventional AA therapy. Furthermore, fish oil does not reduce inflammation or oxidative stress markers in this population, which may explain its lack of efficacy. (Multi-center Study to Evaluate the Effect of N-3 Fatty Acids [OMEGA-3] on Arrhythmia Recurrence in Atrial Fibrillation [AFFORD]; NCT01235130).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.